Current Clinical Trials
University of Pennsylvania
Drs. Carreno, Linette, June
NCT07594067 is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in adult patients with histologically confirmed metastatic pancreatic adenocarcinoma (PDAC), cholangiocarcinoma (CCA), colorectal cancer (CRC), or non-small cell lung cancer (NSCLC). Tumors must harbor a KRAS G12V mutation and patients must be HLA-A*11:01. Up to 4 TCR1188-ABC dose levels will be evaluated.
Eligible patients will receive lymphodepleting chemotherapy, TCR1188-ABC cells, and tocilizumab. TCR1188-ABC cells will be manufactured by the Biopharmaceutical Development Program at the Frederick National Laboratory for Cancer Research (FNLCR), National Cancer Institute. The study is open to enrollment as of July 2026 at the University of Pennsylvania.
Stanford University / Stanford Medicine Children’s Health
IND Sponsor: Crystal Mackall, MD
GPC2 CAR T-Cell Therapy for Relapsed or Refractory CNS Embryonal Tumors
Principal Investigators: Katherine Ryan, DO; Sabine Heitzeneder, MD
Stanford is conducting an investigator-initiated Phase 1 clinical trial evaluating intracerebroventricular (ICV) GPC2-directed CAR T-cell therapy for children and young adults with relapsed or refractory medulloblastoma and other CNS embryonal tumors (ClinicalTrials.gov: NCT07087002).
GPC2 is an oncofetal surface antigen broadly expressed across pediatric embryonal brain tumors, including medulloblastoma, ETMR, ATRT, pineoblastoma, and CNS neuroblastoma, FOXR2-activated. This first-in-human study evaluates the safety, feasibility, and preliminary clinical activity of locoregional GPC2 CAR T-cell therapy delivered via an intraventricular catheter following lymphodepleting chemotherapy.
Current Progress
The Phase 1 study is actively enrolling participants. Building on this platform, Stanford is developing a next-generation cJun-enhanced GPC2 CAR T-cell study through the Can-ACT network, with study activation anticipated next year.
Clinical Trial Inquiries
Please email gpc2cart@stanfordchildrens.org
Memorial Sloan Kettering
Principal Investigator: Dr. Adusumilli
A Multicenter, Phase I/II Trial to Assess the Safety of Autologous Mesothelin-Targeted CAR T-cell Therapy with CD28 and KITv costimulatory domains and PD1 dominant negative receptor in Patients with Diffuse Pleural Mesothelioma
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at the NCI Biopharmaceutical Development Program to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Tumor-targeted radiotherapy will be given prior to the CAR T-cell infusion. Participant study therapy will take about 2-3 weeks.
Participant Group/Arm
Participants diagnosed with mesothelin-positive diffuse pleural mesothelioma who had disease progression or stable and measurable disease or treatment intolerance after receiving at least one prior line of systemic therapy.
Intervention/Treatment
Biological: M28zKITvPD1DNR
Participants with diffuse pleural mesothelioma will be treated with a systemic infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28zKITvPD1DNR CAR. The CAR T cells will be manufactured in a laboratory at the NCI Biopharmaceutical Development Program.